Patent Number: 8,815,511

Title: Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

Inventors: Tchelet; Amir (Hod-Hasharon, IL), Mucciardi; Fabio (Irvine, CA), Levy; Joseph (Kfar-Sava, IL)

Assignee: Teva Pharmaceutical Industries, Ltd.

International Classification: A61K 38/16 (20060101); C12Q 1/68 (20060101)

Expiration Date: 8/26/12018